AlzeCure Pharma
11.10.2021 10:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 11, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company's latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815803/neurology-seminar-cns-3 . The presentation will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Image Attachments
Johan Sandin CSO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/667525/AlzeCure-Presents-at-Redeye-Neurology-CNS-Seminar-on-October-13
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call15.7.2026 22:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / July 15, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q2 2026 earnings before the market opens on Thursday, August 6, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loargro
Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering15.7.2026 14:30:00 CEST | Press release
Flexible convertible structure with shareholder-friendly capped call minimizes dilution Proceeds strengthen liquidity in midst of customer and partner negotiations and preserve Fermi's speed-to-power advantage Attractive five-year cost of capital provides run room to advance multiple commercial tracks in parallel DALLAS, TX / ACCESS Newswire / July 15, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), outlined today the strategic rationale for its recently closed and upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031 (the "Notes"), which included the exercise in full of the initial purchasers' 13-day option to purchase up to an additional $56.25 million aggregate principal amount of Notes. The Notes are intended to strengthen Fermi's balance sheet, enhance liquidity, and support continued execution of Project Matador as the Company advances tenant, strategic partnership, and power-de
Innodata to Report Second Quarter 2026 Results15.7.2026 14:30:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / July 15, 2026 / INNODATA INC. (NASDAQ:INOD) today announced that it will report Second Quarter 2026 results after the market closes on Thursday, August 6, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 715 9871 North America, Toll Free (+44) 800 358 0970 United Kingdom (+1) 646 307 1963 International Participant Access Code 3150581 For Replay: (+1) 800 770 2030 North America-Toll Free (+44) 203 433 3849 (+1) 609 800 9909 United Kingdom International Playback ID 3150581# Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only
UK Renewable Energy Installer Announces Strategic Partnership to Advance Battery Energy Storage Solutions15.7.2026 13:45:00 CEST | Press release
Excel Energy, a UK renewable energy installer, has announced a strategic partnership with global battery innovator Sigenergy to improve how UK businesses store and use surplus solar energy. LONDON, UK / ACCESS Newswire / July 15, 2026 / The collaboration, which began in April 2026, aims to support the deployment of more efficient energy storage systems that help organisations reduce operational energy costs and progress towards net zero targets. The partnership focuses on enabling businesses to capture excess solar generation and deploy it during peak demand periods, overnight usage, or when grid reliance would otherwise be higher. This approach supports more efficient use of on-site renewable generation and improved overall energy management. By integrating advanced battery storage technology with commercial solar installations, the collaboration is intended to enhance energy resilience for businesses while reducing dependence on grid-supplied electricity. It also supports wider adopt
LiberNovo 2026 Chair Lineup Marks One Month on Sale as Early Bird Savings Enter Final Countdown15.7.2026 10:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 15, 2026 / The LiberNovo 2026 lineup, made up of the Omni SE, Omni Pro, and Maxis Series, has reached one month on sale, and its first-release early bird pricing has entered the final stretch. Offers end July 31 at 5:00 p.m. BST in the UK and 6:00 p.m. CEST across the EU. Orders placed before the deadline lock in launch pricing on every model. All three chairs are built on LiberNovo's dynamic support system, which keeps the backrest, neck support, seat, and armrests moving together as you shift, lean, and recline through five stages from 105° to 160°. Three Chairs, One Dynamic Support System The Omni SE keeps things simple. It runs on the same dynamic support, working mechanically with no motor or battery; you set the lumbar depth by hand and the chair does the rest. It ships in Obsidian at the most accessible price in the lineup. The Omni Pro is the premium chair in the lineup. Powered lumbar adjustment and the OmniStretch guided back stretch run
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom